Rani Therapeutics develops oral drug-delivery technologies that enable large biologic molecules (peptides, proteins) to be administered orally rather than by injection. The company’s RaniPill platform is designed to protect biologics through the digestive tract and deliver them directly into the small intestine via a transient, safe mechanical mechanism potentially transforming treatment pathways for chronic conditions. Rani pairs device engineering with drug formulation expertise, IP protection and scalable manufacturing to create alternatives to injectable biologics with improved patient convenience and adherence.
What Is Rani Therapeutics and What Does It Do?
Rani Therapeutics, founded in 2012 by a team led by Mir Imran, is a San Jose–based (United States) biotechnology and delivery-platform company developing oral delivery solutions for large-molecule therapeutics. The company employs 51–200 people and focuses on enabling oral administration for biologics across indications such as endocrinology, autoimmune disease and metabolic disorders. Rani’s platform blends drug formulation, capsule/device engineering and clinical development to replace injectable regimens with patient-friendly oral dosing when possible.
How Much Funding Has Rani Therapeutics Raised?
1. Post-IPO (Oct 23, 2025)
- Amount Raised: $60.3M
- Date: October 23, 2025
- Lead Investors: Public market / institutional participation (post-IPO)
- Motivation: Advance pivotal clinical programs and scale manufacturing.
2. Series E (2020 tranches)
- Amount Raised: $69M (Dec 10, 2020) and $50M (Nov 13, 2020)
- Date: Dec 10, 2020; Nov 13, 2020
- Lead Investors / Facilitators: Bank of America facilitated Series E activity; strategic pharma partners engaged.
- Motivation: Clinical development and manufacturing scale.
3. Series D / Earlier
- Amount Raised: Multiple tranches (2017–2018 Series D $39M; 2015–2018 Series C/D increments totaling earlier commitments)
- Date: 2015–2018 (various)
- Lead Investors: Google Ventures, Ping An Ventures, InCube Ventures, corporate partners like Novartis and AstraZeneca (strategic collaborations)
- Motivation: Technology validation, device engineering and early clinical work.
Total Funding Raised: $234 Million
Latest Funding Date: October 2025
Key Investors
1. Google Ventures (GV)
- Details: VC arm focused on transformative biotech and platform technologies.
- Investment Focus Areas: Biotech platforms, device-drug combos.
- Notable Investments: Verily, Flatiron Health, other life-science innovators.
2. Nan Fung Life Sciences / Alpha Square (representative backers)
- Details: Life sciences investors supporting biologics and medical device platforms.
- Investment Focus Areas: Therapeutics, delivery platforms.
- Notable Investments: Select clinical-stage biotech companies.
Where Is Rani Therapeutics’ Headquarters?
Rani Therapeutics is headquartered in San Jose, United States, placing it near Bay Area life-science engineering and manufacturing partners.
What’s Next for Rani Therapeutics?
Rani will focus on advancing pivotal clinical studies for oral biologic candidates, scaling GMP manufacturing of its device platform, and pursuing strategic partnerships to commercialize oral alternatives for injectable therapeutics.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like Rani Therapeutics. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.
